Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma

Abstract

Background: Emerging evidences have indicated that IRF6, as a member of the Interferon regulatory factors (IRFs) family, plays important roles in a variety of tumors. However, the expression status of IRF6 and its prognostic value in clear cell renal cell carcinoma (ccRCC) remain unclear. Methods: In this study, we used TCGA-KIRC, GEO and TIP databases and immunohistochemistry staining to determine the expression profile, clinico-pathological features and prognostic value of IRF6 in ccRCC. MSP and demethylation analysis were utilized to verify the regulatory effect of DNA methylation on IRF6 expression. Results: Our results found that IRF6 expression was downregulated in ccRCC tissues and cell lines, and decreased IRF6 expression was associated with worse clinicopathological features and poorer prognosis. Besides, the results of multivariate Cox regression analysis also confirmed that decreased IRF6 expression was an independently risk factor predictor of shorter Overall Survival (OS) (HR: 0.8524, 95%CI: 0.7614-0.9543, P=0.0056) and Disease Free Survival (DFS) (HR: 0.7024, 95%CI: 0.6087-0.8104, P<0.0001) in ccRCC patients. Moreover, the results of MSP and demethylation analysis validated that decreased IRF6 expression was caused by DNA hypermethylation. Furthermore, our results showed that IRF6 expression was associated with the infiltration levels of multiple immune cells in ccRCC. Conclusions: These findings demonstrated that IRF6 expression was significantly reduced in ccRCC and DNA hypermethylation played an important role in decreased IRF6 expression. In addition, the decrease of IRF6 was related to the unfavorable prognosis of ccRCC patients and the alterations of tumor immune cells infiltration.

M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy

“…It has been reported that overexpression of PDHA1 can inhibit aerobic glycolysis and result in mitochondria-mediated apoptosis in hepatocellular cancer 41 . Additionally, other surveys elucidated that PDHA1 might play an antitumour role in cancer and that low expression of PDHA1 predicted a poor outcome in these tumours 42 , 43 . However, compared to Warburg effect-dependent cancer cells, several kinds of cancer rely on the TCA cycle as well.…”

Systematic analysis of the cuprotosis in tumor microenvironment and prognosis of gastric cancer

“…FDX1 impacted the prognosis of lung adenocarcinoma and was closely related to glucose metabolism, fatty acid oxidation and amino acid metabolism [ 71 ]. Decreased PDHA1 expression was associated with poor overall survival of individuals with oesophageal squamous cell carcinoma, prostate cancer, ovarian carcinoma, and GC [ [72] , [73] , [74] , [75] ]. Likewise, in this study, the risk score of four cuprotosis genes, LIAS, FDX1, PDHA1 and DLD, could predict GC prognosis.…”

Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer

“…Several studies have found that the expression level of the PDHA1 gene is elevated in various cancers such as ovarian cancer, and high expression levels are closely related to the malignancy and prognosis of tumors. In addition, the PDHA1 gene is involved in regulating the oxidative stress response of tumor cells, enabling them to acquire stronger antioxidant capabilities and survival advantages, thereby promoting tumor cell growth and metastasis ( 82 , 83 ). Some studies have also suggested that the PDHA1 gene may act as a potential tumor suppressor gene in gastric and renal cell carcinoma, and its mutations or deletions can lead to disruptions in cellular energy metabolism and inhibition of autophagy and apoptosis, and promote tumor formation and development ( 84 , 85 ).…”